Filters

Rebecca Mather, Chrysanthi Matheou, Erik Venalainen, Perla Pucci, Roberto Silvestri, Francesco Crea, Martin David Bootman, Katja Rietdorf, Yuzhuo Wang, Sushilaben H Rigas, Romina Aceto, Stephen Chandler

The Prostate 2020;79(13):1580-1586

Full Text

Abstract

Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone.

T Varis, J T Backman, K T Kivistö, P J Neuvonen

Clinical pharmacology and therapeutics 2000;67(3):215-21

Full Text

Abstract

Comparison of the efficacy and safety of losartan (50-100 mg) with the T-type calcium channel blocker mibefradil (50-100 mg) in mild to moderate hypertension.

O Chung, M Hinder, A M Sharma, G Bönner, M Middeke, J Platon, T Unger

Fundamental & clinical pharmacology 2000;14(1):31-41

Full Text

Abstract

Different effects of calcium antagonist and beta-blocker therapy on left-ventricular diastolic function in ischemic heart disease. A direct comparison of the impact of mibefradil and atenolol.

C Hassager, K Thygesen, P Grande, J Fischer Hansen, H Mickley, I Gustafsson, K Skagen, F Steensgaard-Hansen

Cardiology 2002;96(2):65-71

Full Text

Abstract

Effect of mibefradil on CYP3A4 in vivo.

Lisa P Gillen, Howard E Greenberg, Walter W Hauck, Ellen P Dorval, Maria L Veronese, Scott A Waldman

Journal of clinical pharmacology 2004;43(10):1091-100

Full Text

Abstract

Results: 1 – 15 / 18

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Mibefradil""[mesh_terms]

T-Type Calcium Channels: A Mixed Blessing.

Versatile applicability of a grid-based CYP3A4 Template to understand the interacting mechanisms with the small-size ligands; part 3 of CYP3A4 Template study.

Randomized comparison of T-type versus L-type calcium-channel blockade on exercise duration in stable angina: results of the Posicor Reduction of Ischemia During Exercise (PRIDE) trial.

Mibefradil, a T-type Ca channel blocker also blocks Orai channels by action at the extracellular surface.

Mibefradil: "Has the baby been thrown out with the bath water?".

The effect of mibefradil on ischemic episodes with and without increase in heart rate.

Comparative effects of mibefradil and nifedipine gastrointestinal transport system on autonomic function in patients with mild to moderate essential hypertension.

Effect of mibefradil on heart rate variability in patients with chronic heart failure.

Effect of mibefradil, a T-type calcium channel blocker, on morbidity and mortality in moderate to severe congestive heart failure: the MACH-1 study. Mortality Assessment in Congestive Heart Failure Trial.

Gating Modulation of the Tumor-Related Kv10.1 Channel by Mibefradil.

T-type calcium channels drive the proliferation of androgen-receptor negative prostate cancer cells.

Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone.

Comparison of the efficacy and safety of losartan (50-100 mg) with the T-type calcium channel blocker mibefradil (50-100 mg) in mild to moderate hypertension.

Different effects of calcium antagonist and beta-blocker therapy on left-ventricular diastolic function in ischemic heart disease. A direct comparison of the impact of mibefradil and atenolol.

Effect of mibefradil on CYP3A4 in vivo.

Results for
""Mibefradil""[mesh_terms]